CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In this study, we showed that the combination of SERPINE1 inhibitor and TKI effectively suppressed the growth of IM-resistant CML CD34+ cells and quiescent CML CD34+ cells, while it had a mild effect on normal control cells.